Tim J. van Oostenbrugge

Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Marye J. Boers‐Sonderen, Tim J. van Oostenbrugge, Otto C. Boerman et al. · European Urology · 2015 · 104 citations

Medicine, Oncology, Pharmacology +15

MRI as a tool to assess surgical margins and pseudocapsule features directly following partial nephrectomy for small renal masses

Tim J. van Oostenbrugge, Willemien Runneboom, Elise M. Bekers et al. · European Radiology · 2018 · 21 citations · Full text

Medicine, Pathology, Surgery +17

The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma

Tim J. van Oostenbrugge, Stephanie Kroeze, J.L.H. Ruud Bosch et al. · World Journal of Urology · 2014 · 20 citations

Medicine, Surgery, Urology +13

Outcome of endovascular reintervention for significant stenosis at infrainguinal bypass anastomoses

Tim J. van Oostenbrugge, Jean‐Paul P.M. de Vries, P. Berger et al. · Journal of Vascular Surgery · 2014 · 17 citations · Full text

Medicine, Surgery, Cardiothoracic Surgery +9

Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab

Tim J. van Oostenbrugge, Johan F. Langenhuijsen, Egbert Oosterwijk et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 15 citations · Full text

Medicine, Oncology, Radiology +17